sns insider pvt ltd.png
Global Vaccine Market Size Expected to Reach USD 186.5 Billion by 2032 with 10.7% CAGR - SNS Insider
October 07, 2024 09:10 ET | SNS Insider pvt ltd
Pune, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Vaccine Market Size & Growth Analysis: According to SNS Insider, The Vaccine Market Size was valued at USD 74.7 billion in 2023 and is expected to...
Sabin Vaccine Institute Marburg Vaccines Arrive in Rwanda
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
October 05, 2024 18:24 ET | Sabin Vaccine Institute
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024. WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has provided...
image1 (1).png
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
September 19, 2024 08:00 ET | Evaxion Biotech
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction featureThe launch will expectedly...
logo.gif
Canada's Only Single-Dose Cholera Vaccine Available Nationwide
September 16, 2024 08:00 ET | Bavarian Nordic A/S
Bavarian Nordic announces availability of VAXCHORA, Canada's only single-dose cholera vaccine for travelers (age 2 to 64) to cholera-affected countries.
image1 (1).png
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
September 16, 2024 07:00 ET | Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
image1 (1).png
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
September 09, 2024 08:00 ET | Evaxion Biotech
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...
image1 (1).png
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
September 09, 2024 07:00 ET | Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Kelly Warfield
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
August 20, 2024 07:00 ET | Sabin Vaccine Institute
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine development leader Kelly Warfield has...
emerge.png
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
August 19, 2024 17:10 ET | Emergent BioSolutions
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox...
Phase2_Clinical_Trial_Sudan_Ebolavirus_Sabin_MUWRP_Kampala_Uganda
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
July 15, 2024 10:29 ET | Sabin Vaccine Institute
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month. WASHINGTON, July 15, 2024 (GLOBE NEWSWIRE) -- Sabin Vaccine...